In a multicohort phase 1 clinical study including patients with various solid tumors, the ORR among HER2-positive NSCLC patients was 72.7% (eight out of 11 patients), whereas the mPFS was 11.3 months (95% CI 8.1–14.3 months). Here, ERBB2 is linked to non-small cell lung carcinoma.